/*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} Problem 5 Which of the following combinati... [FREE SOLUTION] | 91影视

91影视

Log out

Learning Materials

Features

Discover

Chapter 41: Problem 5

Which of the following combinations will not be recommended for first line therapy in a patient with HIV associated dementia? a. Zidovudine plus lamivudine plus efavirenz b. Tenofovir plus emtricitabine plus lopinavir/ritonavir c. Tenofovir plus emtricitabine plus atazanavir/ritonavir d. Lamivudine plus abacavir plus fosamprenavir e. Zidovudine plus lamivudine plus abacavir

Short Answer

Expert verified
Answer: Zidovudine + lamivudine + abacavir

Step by step solution

01

Review the recommended first-line therapy options for HIV associated dementia

To answer this question, we must first know the standard recommendations for first-line therapy in patients with HIV associated dementia. According to the current guidelines, the preferred first-line options include combinations of two nucleoside reverse transcriptase inhibitors (NRTIs) such as lamivudine, emtricitabine, zidovudine, and tenofovir, paired with a non-nucleoside reverse transcriptase inhibitor (NNRTI) like efavirenz or a boosted protease inhibitor (PI) such as lopinavir/ritonavir or atazanavir/ritonavir.
02

Evaluate each combination

Now let's examine each of the given combinations to find the one that is not recommended for first-line therapy in a patient with HIV associated dementia. a. Zidovudine + lamivudine + efavirenz: This combination fits the recommended pattern of two NRTIs (zidovudine and lamivudine) plus an NNRTI (efavirenz). Efavirenz has been associated with CNS side effects, however, it has been used effectively in patients with HIV associated dementia. b. Tenofovir + emtricitabine + lopinavir/ritonavir: This combination contains two NRTIs (tenofovir and emtricitabine) plus a boosted PI (lopinavir/ritonavir), which aligns with the recommended first-line therapy options. c. Tenofovir + emtricitabine + atazanavir/ritonavir: This combination also contains two NRTIs (tenofovir and emtricitabine) plus a boosted PI (atazanavir/ritonavir), fitting the recommended first-line therapy options. d. Lamivudine + abacavir + fosamprenavir: This combination includes two NRTIs (lamivudine and abacavir) but the third drug, fosamprenavir, is a protease inhibitor that is not typically recommended as first-line therapy, especially in patients with HIV associated dementia. e. Zidovudine + lamivudine + abacavir: This combination consists of three NRTIs (zidovudine, lamivudine, and abacavir). The recommended first-line therapy includes two NRTIs and either an NNRTI or a boosted PI, so this combination does not fit the standard guidelines.
03

Identify the not recommended combination

Based on our evaluation, the not recommended combination for first-line therapy in a patient with HIV associated dementia is: e. Zidovudine + lamivudine + abacavir

Unlock Step-by-Step Solutions & Ace Your Exams!

  • Full Textbook Solutions

    Get detailed explanations and key concepts

  • Unlimited Al creation

    Al flashcards, explanations, exams and more...

  • Ads-free access

    To over 500 millions flashcards

  • Money-back guarantee

    We refund you if you fail your exam.

Over 30 million students worldwide already upgrade their learning with 91影视!

Key Concepts

These are the key concepts you need to understand to accurately answer the question.

First-Line Therapy
First-line therapy in the context of HIV associated dementia is the initial treatment strategy recommended for patients. This aims to control the virus while managing symptoms associated with dementia. The goal is to select drugs that work well together and have the least negative impact on cognitive function.

For HIV associated dementia, the standard first-line therapy involves two components:
  • Two nucleoside reverse transcriptase inhibitors (NRTIs).
  • Either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a boosted protease inhibitor (PI).
This combination seeks to maximize antiviral efficiency while minimizing cognitive side effects. Understanding these treatment guidelines is crucial to ensure both the effectiveness of the therapy and the quality of life for the patient.
Nucleoside Reverse Transcriptase Inhibitors
Nucleoside Reverse Transcriptase Inhibitors, or NRTIs, are a cornerstone in the treatment of HIV. They act by blocking reverse transcriptase, an enzyme the virus needs to replicate and spread throughout the body. When the virus is unable to reproduce effectively, it helps control the infection and lowers the viral load in the patient's system.

Common NRTIs include:
  • Zidovudine
  • Lamivudine
  • Emtricitabine
  • Tenofovir
  • Abacavir
These drugs are typically used in pairs within the first-line therapy to bolster the antiviral effect. However, choosing the right combination is essential to avoid unwanted interactions and side effects, especially in patients with pre-existing conditions like dementia.
Non-Nucleoside Reverse Transcriptase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors, abbreviated as NNRTIs, provide another means of tackling HIV by blocking the same enzyme targeted by NRTIs, although they do so in a different manner. Unlike NRTIs, which mimic the nucleosides that make up the viral DNA, NNRTIs attach directly to the reverse transcriptase enzyme, inhibiting its function effectively.

Efavirenz is a well-known NNRTI that is often used in first-line therapy. Though effective, it can lead to side effects involving the central nervous system (CNS), which is a critical consideration in managing HIV associated dementia.

Utilizing NNRTIs such as efavirenz in treatment plans needs careful evaluation to balance their efficacy with these potential CNS-related side effects.
Protease Inhibitors
Protease Inhibitors (PIs) are another vital class of drugs in combined antiretroviral therapy for HIV. They prevent the virus from maturing by blocking the protease enzyme, a crucial step in the viral replication cycle. When the virus is not able to mature, it cannot infect new cells as effectively.

Common PIs used include:
  • Lopinavir/ritonavir
  • Atazanavir/ritonavir
  • Fosamprenavir (though not typically first-line for dementia)
Usually combined with two NRTIs in therapy, boosted PIs like lopinavir/ritonavir and atazanavir/ritonavir are often preferred because they tend to maintain their efficacy in the presence of resistance and have fewer CNS side effects compared to some NNRTIs. Despite their effectiveness, the decision to use PIs must always consider the specific needs of patients, especially those with HIV associated dementia, to optimize both treatment outcomes and patient wellbeing.

One App. One Place for Learning.

All the tools & learning materials you need for study success - in one app.

Get started for free

Most popular questions from this chapter

What aspects of clinical care have impacted the natural history of cognitive impairments in HIV infected individuals? a. The introduction of potent, combination anti-retroviral therapy b. The use of prophylactic medications against opportunistic infections c. Improved biomarkers for disease diagnosis d. One and two e. None of the above

A patient with HIV-associated dementia receiving antiretroviral therapy presents with a burning sensation in feet and hands, numbness and tingling in the feet, cramps in the legs, and absent ankle reflexes. What drug will you be the LEAST likely to blame on his/her new symptoms? a. Zidovudine b. Stavudine c. Didanosine d. Zalcitabine e. All of the above can cause the patient's symptoms

Which of the following drug classes are not currently licensed for the treatment of HIV disease? a. Nucleoside reverse transcriptase inhibitors b. Non-nucleoside reverse transcriptase inhibitors c. Protease inhibitors d. Entry inhibitors e. Inhibitors of viral maturation

What is correct about the "Trojan Horse" model of HIV invasion into the CNS? a. Proposes that monocyte-macrophage carry progeny virions from blood to the brain inside cytoplasmic vacuoles and across the blood-brain barrier b. Requires an inflammatory response in the brain, which elicits a chemokine gradient c. After infiltrating the brain parenchyma, blood borne monocyte-macrophages also release additional chemokines and further attract additional inflammatory cells d. Does not require productive viral replication in brain microvascular endothelial cells e. All of the above

Antiretroviral agents currently in use include inhibitors of reverse transcriptase, HIV protease, and fusion inhibitors. True/False
See all solutions

Recommended explanations on Biology Textbooks

Biological Organisms

Read Explanation

Cell Communication

Read Explanation

Biological Processes

Read Explanation

Cell Cycle

Read Explanation

Astrobiological Science

Read Explanation

Bioenergetics

Read Explanation
View all explanations

What do you think about this solution?

We value your feedback to improve our textbook solutions.

Study anywhere. Anytime. Across all devices.